# Observational Studies in Action

## Schedule

Note: You can read the abstracts for all selections [at this link](https://github.com/THOMASELOVE/500-classes-2026/blob/main/osia/abstracts/README.md).

## Class 09: 2026-03-26

First Reader | Second Reader | Article 
:------------: | :-------------: | :-----------------------------------------------------------------------------------------------
Kathryn Menta | Megan Zelinsky | Tran et al. 2026 *JAMA Network Open* 9(1): e2553157. <br/> [Role of Chronic Conditions in Out-of-Pocket Costs for](articles/Tran2026_main.pdf) <br/> [Preventive Care in the US](articles/Tran2026_main.pdf) <br/> **Supplements** (1 PDF, 1 Excel) found on our Shared Drive.
Feriel Presswalla | Mariam Zayour | Huang YN et al. 2024 *Diabetes Obes Metab* 26: 5222-5232. <br/> [Long-term safety and efficacy of glucagon-like peptide-1 receptor](articles/HuangYN2024_main.pdf) <br/>  [agonists in individuals with obesity and without type 2 diabetes:](articles/HuangYN2024_main.pdf) <br/> [A global retrospective cohort study](articles/HuangYN2024_main.pdf) <br/> **Supplement** (1 PDF) found on our Shared Drive.
Wala'a Alshaia | Lily Zhang | Wang et al. 2024 *JAMA Network Open* 7(7): e2421305. <br/> [Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated](articles/Wang2024_main.pdf) <br/> [Cancers in Patients With Type 2 Diabetes](articles/Wang2024_main.pdf) <br/> **Supplement** (1 PDF) found on our Shared Drive.
Jeff Lambe | Kathryn Menta | Barbuti et al. 2025 *Neuropathics* 22, e00537. <br/> [Comparative effectiveness, safety and persistence of ocrelizumab](articles/Barbuti2025_main.pdf) <br/> [versus natalizumab in multiple sclerosis:](articles/Barbuti2025_main.pdf) <br/> [A real-world, multi-center, propensity score-matched study](articles/Barbuti2025_main.pdf) <br/> No supplements.

## Class 10: 2026-04-02

First Reader | Second Reader | Article 
:------------: | :-------------: | :-----------------------------------------------------------------------------------------------
Fai Albuainain | Wala'a Alshaia | Rogerson et al. 2024 *Pediatric Pulmonology* 59: 3457-34766. <br/> [A matched analysis of the use of high flow nasal cannula](articles/Rogerson2024_main.pdf) <br/> [for pediatric severe acute asthma](articles/Rogerson2024_main.pdf) <br/> **Supplement** (1 PDF) found on our Shared Drive.
Megan Zelinsky | Jeff Lambe | Ferreira-Atuesta et al. 2026 *Neurology* 106: e214613 <br/> [Timing for Starting Antiseizure Medication Withdrawal after](articles/Ferreira-Atuesta2026_main.pdf) <br/> [Epilepsy Surgery in Adults](articles/Ferreira-Atuesta2026_main.pdf) <br/> **Supplement** (1 PDF) found on our Shared Drive.
Mariam Zayour | Fai Albuainain | Palzes et al. 2026 *Biological Psychiatry: Global Open Science* 16:100659 <br/> [Glucagon-Like Peptide-1 Receptor Agonists and Alcohol Use:](articles/Palzes2026_main.pdf) <br/> [A Real-Word Observational Study in a Large, Integrated](articles/Palzes2026_main.pdf) <br/> [Health Care System](articles/Palzes2026_main.pdf) <br/> **Supplements** (1 PDF, 1 Excel) found on our Shared Drive.
Lily Zhang | Thomas Love | Hung SK et al. 2023 *Breast Cancer Research* 25: 149. <br/>  [Molecular subtypes of breast cancer predicting clinical benefits](articles/HungSK2023_main.pdf) <br/> [of radiotherapy after breast-conserving surgery:](articles/HungSK2023_main.pdf) <br/> [A propensity-score-matched cohort study](articles/HungSK2023_main.pdf) <br/> No supplements.

## Class 11: 2026-04-02

First Reader | Second Reader | Article 
:------------: | :-------------: | :-----------------------------------------------------------------------------------------------
Saar Anis | Feriel Presswalla | Siddeeque et al. 2024 *International Immunopharmacology* 143: 113537. <br/> [Neuroprotective effects of GLP-1 receptor agonists](articles/Siddeeque2024_main.pdf) <br/> [in neurodegenerative disorders:](articles/Siddeeque2024_main.pdf) <br/> [A Large-Scale Propensity-Matched cohort study](articles/Siddeeque2024_main.pdf) <br/> **Supplement** (1 PDF) found on our Shared Drive.



